Patents by Inventor Pilar de la Puente

Pilar de la Puente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220228124
    Abstract: The disclosure provides three-dimensional cross-linked scaffolds generated from peripheral blood plasma, and methods for making and using such scaffolds.
    Type: Application
    Filed: June 15, 2019
    Publication date: July 21, 2022
    Inventors: Pilar DE LA PUENTE, Somshuvra BHATTACHARYA, Kristin CALAR
  • Publication number: 20220213433
    Abstract: The disclosure provides three-dimensional cross-linked scaffolds generated from cord blood plasma, and methods for making and using such scaffolds.
    Type: Application
    Filed: June 15, 2020
    Publication date: July 7, 2022
    Inventors: Michelle BAACK, Pilar DE LA PUENTE, Tyler GANDY
  • Patent number: 10548996
    Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 4, 2020
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Abdel Kareem Azab, Pilar de la Puente, Feda Azab
  • Patent number: 10463764
    Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 5, 2019
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Abdel Kareem Azab, Pilar de la Puente
  • Publication number: 20190269792
    Abstract: The present disclosure discloses compositions, and methods of making and using nanoparticles to treat multiple myeloma.
    Type: Application
    Filed: October 25, 2017
    Publication date: September 5, 2019
    Applicant: Washington University
    Inventors: Abdel Kareem Azab, Maria del Pilar de la Puente Garcia
  • Publication number: 20170232146
    Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Inventors: Abdel Kareem Azab, Pilar de la Puente
  • Publication number: 20170209606
    Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 27, 2017
    Inventors: Abdel Kareem Azab, Pilar de la Puente, Feda Azab
  • Patent number: 9675732
    Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 13, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Abdel Kareem Azab, Pilar de la Puente
  • Publication number: 20160136327
    Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 19, 2016
    Inventors: Abdel Kareem Azab, Pilar de la Puente